Business:
Therapies for the treatment of metastatic cancers
Drug notes:
VLS-1488 Clin0 oncology; 2 undisclosed programs RD oncology
About:
Volastra Therapeutics is developing drugs that target a vulnerability of cancer cells - chromosomal instability, or CIN. CIN is present in 60-80% of cancers and is associated with poor survival in many patients. By using their proprietary CINtech platform that incorporates cancer biology, data sciences and medicinal chemistry, Volastra is turning a deep biological understanding of CIN into life-saving therapies. The tools Volastra is using range from CIN CRISPR screen, CIN imaging and genomics to molecular structure-activity analysis. Volastra is initially focusing on two therapeutic approaches: synthetic lethality and immune activation, with programs in early development.
Data Engineer/Senior Data Engineer New York City, NY|19 days ago
Scientist/Manager, Translational Science and Bioma... New York City, NY|25 days ago
Clinical Scientist (Manager/Senior Manager), Oncol... New York City, NY|28 days ago
Senior/Medical Director, Oncology New York City, NY|28 days ago
Scientist / Senior Scientist, Protein Biochemistry... New York City, NY|39 days ago
Director, Development Program Management, Oncology... New York City, NY|100+ days ago